+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Part the Cloud Translational Research for Alzheimer’s Disease Program

Alzheimer’s Association

The Alzheimer's Association is pleased to announce the next offering of the Part the Cloud (PTC) Translational Research Funding initiative to increase the research efforts in Phase I and Phase II (Proof of Concept) clinical trials evaluating novel or repurposed potential medications directed towards Alzheimer’s disease and related dementias internationally.

This grant is open to U.S. and international researchers.

Potential themes

This new grant mechanism aims to fill the gap in Alzheimer’s disease and related dementia clinical trials for advancing potential therapeutics forward by providing support for early phase studies (Phase 1 and Phase 2).

Funding and award period

Each grant is limited to $1,000,000 (direct and indirect costs) over two or three years. Indirect costs are only allowed for not-for-profit institutions, and are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution). No indirect costs are allowed for profit organizations.

Letter of intent review procedures

All applicants must submit a Letter of Intent (LOI) through Proposal Central. Hard copies or email submissions will not be accepted. First-time users must register and complete a Professional Profile before submission. The LOI must be submitted by a single Principal Investigator (PI) and within the active grant cycle; late submissions will not be considered.

The LOI ensures applicant eligibility and alignment with program priorities while aiding in the review process. Applicants must provide essential details, including PI and institution information, project title, area of focus, and a brief project description (up to 1,000 characters each, including spaces) covering methodology, aims, innovation, and anticipated impact. ORCID ID and a signed institutional W9 or W8 form are required, along with a biosketch for the PI. Budget details are not required at this stage.

All LOIs will be evaluated prior to invitation to submit a full application. Only LOIs that meet program specific guidelines as outlined in this request for applications will be invited to submit full applications.

Letter of intent deadline

Letters of Intent (LOI) must be received by 5:00pm EST, August 6, 2025. Letters of Intent will not be accepted after this date. No exceptions will be made. If the on-line LOI is approved and invited to submit a full proposal, an email notification will be sent from Proposal Central granting access to the on-line application. The online system must be used to submit a grant application; hard copies of the application will not be accepted.

Each LOI is evaluated with attention to:

Demonstrable innovation/novelty of the proposed project (especially in the context of the PIs recently funded work)
Alignment with the research priorities of the PTC request for applications and the Alzheimer’s Association
Impact of project on Alzheimer’s and all other dementia research
Evidence of methodological rigor that address the research question(s) being proposed

Full application requirements

Once an LOI is approved, applicants will be invited to submit a full application through Proposal Central. Detailed instructions and templates will be available in the system. Submissions must be completed by the specified deadline, and late or incomplete applications will not be considered.
For those invited to submit, Full applications must be received by 5:00pm EST, September 24, 2025.

Problem Statement – 1 page.
Work Plan – 5 pages; Efficacy should not be the primary outcome for studies at phase 1 and phase 2; however, it may be an exploratory outcome. All applications should have clear Go/No Go criteria to the next phase of clinical development of the therapy, which should be clearly outlined in the application. The application must demonstrate how data from the proposed study will inform future trials.
Available Resources & Budget Justification – 2 pages; If awarded, a full budget of planned expenses will be required.
Data Management and Sharing Plan – 3 pages; we recommend using the provided amended NIH template. When data sharing may be limited, applicants must explain such limitations at the time of application.
Recruitment Plan - 1 page; the Association expects all trials to match or exceed the diversity of their local population at a minimum. Award must maintain representation of the community the study is being conducted.
Milestones – 3 pages max.
Reference and Citations – 1 page.
Response to review comments – For resubmissions only – 1 page.
Therapeutic Rationale – 1 page.
Gannt Chart – 1 page (Optional).
Biosketch (PI/Co-PI/Key Personnel) – 5 pages max for each.
Research Project Leadership Plan – 5 pages max.

Applications will be reviewed with special attention to:

Significance of the question being studied and rationale of the target being pursued
Applicant information
Quality of the proposed trial design
Quality and adequacy of available resources and budget
Impact-risk

Scientific and technical review will be conducted in October 2025 – November 2025. The second level review by the Alzheimer’s Association and subject matter experts in November and funding is anticipated to be awarded by November 15, 2025.

Deadlines and award dates

Letter of Intent Launch: June 1
LOI submission deadline: August 6
Full proposal invitations: August 20
Application submission Deadline: September 24
Application Review: September/October/November
Award Notification: November 15

The Letter of Intent and application must be submitted by 5:00 PM Eastern Time on the respective deadlines. Late submissions, hard copies, or email submissions will not be accepted.

Reporting requirements

Awardees will be required to provide sixth month milestones and have bi-annual discussions with the Alzheimer’s Association. Annual scientific progress and financial reports are required. Continuation of the grant over the awarded duration is contingent upon meeting the scientific milestones, and upon timely receipt of scientific and financial reports. Representation of study participants should be reflective of the communities that are being engaged for this study.

Budget

A budget summary for the proposed research project is required and must be submitted with the application and within the allowable page limits. However, if the application is to be awarded, a more detailed budget will be required and must be approved before the disbursement of funds. Your budget must not exceed the maximum amount of the award, $1,000,000 (inclusive of direct and indirect) over two or three years. Costs associated with the management and sharing of research data are allowable. Costs related to participant remuneration should follow the recommendations proposed by the National Alzheimer’s Coordinating Center (NACC).

Costs not allowed under this award include:

Computer hardware or software for investigators (e.g. Microsoft Office, mouse, monitor, computer parts).
Laboratory equipment such as freezers, ultracentrifuges, RT-PCR, Microscopy/imaging equipment.
Service contract fees of equipment.
Construction or renovation costs.
Tuition.
Rent for laboratory/office spaces.
Expenses such as Data Network Recharges and Computing and communication devise support services.
General liability insurances, such as GAEL.
Wire and currency exchange fees.
Salary and/or compensation for Alzheimer’s Association Staff or current members of the Alzheimer’s Association Medical and Scientific Advisory Group (MSAG) and the International Research Grant Program (IRGP) Council. A complete list of MSAG and IRGP Council members can be found on our website at alz.org/grants.

AI Based Application Success Predictor

🎯 1. Focus on Novel, Translational Science

Prioritize projects that translate into patient impact: 

Basic science with potential for treatment, early detection, or prevention strategies

Discovery grants that leverage shared models and data (e.g., MODEL‑AD) and collaborate across disciplines

🌍 2. Support for Diversity & Health Equity

The Association emphasizes inclusivity across both workforce and research populations

Programs like Research Grant New to Field to Promote Diversity (AARG‑D) provide ~$200K to underrepresented early-career researchers

Over 10% of funded projects address health disparities, policy, or ethics in dementia care

📊 3. Multi-Stage Peer Review & Competitive Rates

High-volume intake (~1,467 LOIs, 984 full proposals in 2024 with ~650 reviewers from 29 countries)

Uses two-tier review: LOI followed by invitation to full application. Only the most competitive advance.

🗓 4. Pathway Funding Across Career Stages & Themes

Offers a broad funding spectrum:

International Research Grants for career-spanning basic-to-care studies

Initiative-specific grants: ALZ-RWD (real-world data), WW-FINGERS (prevention network), Gene Targeting Challenge, and dementia care (e.g., Center for Dementia Respite Innovation)

🔗 5. Collaboration & Data Leverage

Projects built on shared models, datasets, or platforms (e.g., AD Knowledge Portal, ALZ-NET) are strongly encouraged

Emphasis on multidisciplinary teams using big data, biomarkers, imaging, or clinical cohorts

💡 6. Innovation & Risk

Opportunities like the Gene Targeting Challenge focus on early-stage, bold interventions for novel genetic targets

✅ Summary Table

Predictor	What to Convey in Your Application
Translational potential	Tie basic findings to diagnostics, prevention, or treatment
Use of shared models/data	Leverage MODEL‑AD, AD Knowledge Portal, ALZ‑NET, etc.
Commitment to diversity	Highlight team or population inclusion and diversity
Budget clarity & LOI strength	Craft strong LOI; follow multi-stage guidance
Team & collaboration	Highlight multi-disciplinarity and platform reach
Focus on equity topics	Align with HPE‑ADRD and other disparity-focused areas

🛠 Recommendations for Applicants

Start with a strong LOI—make it novel, feasible, and platform-linked.

Emphasize the translational pathway—e.g., how your project could affect early detection, prevention, or care.

Connect with shared resources—indicate how you will use shared models, data platforms, or networks.

Support diversity—as PI, team member, population focus, or health disparity dimension.

Select the right mechanism—e.g., ALZ‑RWD for real-world data, Gene Targeting for genetic innovation, or AARG‑D for diversity-enhancing proposals.

Prepare for competitive, multi-stage review—LOI → invitation → full application. Address feedback and align tightly with priorities.

Specialties

Neurosciences

Eligibility Requirements

Applications will be accepted from academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior (Phase 1) to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study in humans to begin proving the scientific concept in humans. This award will support Phase 1 studies or pilot small- scale Phase 2a studies for repurposed drugs in normal individuals or individuals with symptomatic or symptomatic Alzheimer’s and related dementia (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. In addition, proposals may be considered that are POC to validate biological marker(s) of disease progression in a clinical trial environment. Any proposal must have a clear focus on Alzheimer’s disease and related disorders and be translational in nature. All proposals should clearly and explicitly outline the measure to be investigated, the methods for study, the study population, and outcomes. Researchers from underrepresented groups are encouraged to apply.

Studies funded by Part the Cloud with results justifying further development (e.g. Phase 2b, or 3) may be eligible to apply to the Alzheimer’s Clinical Trials Consortium (ACTC) (U24 AG057437). ACTC provides comprehensive infrastructure and expertise on ADRD clinical trials. ACTC and the proposer will work in collaboration to develop a grant application to National Institute on Aging, NIH. If funded, ACTC will conduct the trial. Mentorship and Principal Investigator training in Alzheimer’s Clinical Trials is provided by ACTC. Read more at: https://www.actcinfo.org/submit-a-proposal.

Both non-profit and small for-profit organizations are eligible. Open to International Applicants. Small for-profit organizations must submit documentation of net assets and annual earnings during the letter of intent process as a part of the review process. Not-for-profit organizations must submit documentation verifying status during the letter of intent process.

Applications will be accepted from organizations conducting studies around the world. Researchers with full-time staff or faculty appointments are encouraged to apply. Applications from post- doctoral candidates will not be accepted. For questions as to whether an investigator or organization is eligible, please contact the Alzheimer’s Association at grantsapp@alz.org.

Note: Alzheimer’s Association grants are generally open to scientists and researchers across the globe; however, as a U.S.-based charity, the Alzheimer’s Association is subject to, and complies with, U.S. law. As a result, the Alzheimer’s Association cannot award, and will not award, grants in violation of applicable U.S. statutes and regulations. This means, among other things, that the Alzheimer’s Association cannot, and will not, fund any individual or entity (i) that is subject to U.S. comprehensive or targeted sanctions or if awarding funding would result in a violation of such sanctions, (ii) that is on the U.S. List of Specially Designated Nationals or entities owned or controlled by such persons, or (iii) when doing so is otherwise prohibited by U.S. laws related to combating terrorism.

Sponsor Details

Sponsor Institute/Organizations: Alzheimer’s Association

Sponsor Type: Corporate/Non-Profit

Address: 225 N Michigan Ave. Floor 17 Chicago, IL 60601 800.272.3900

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity